Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.
about
Inhibition of hepatic lipogenesis enhances liver tumorigenesis by increasing antioxidant defence and promoting cell survival.Fatty acid synthase reprograms the epigenome in uterine leiomyosarcomas.Inhibition of Acetyl-CoA Carboxylase 1 (ACC1) and 2 (ACC2) Reduces Proliferation and De Novo Lipogenesis of EGFRvIII Human Glioblastoma Cells.Lipid quantification by Raman microspectroscopy as a potential biomarker in prostate cancer.Anticancer agents: ACC inhibition suppresses lung cancer.AMPK β1 reduces tumor progression and improves survival in p53 null mice.Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus.Oncogene dependent requirement of fatty acid synthase in hepatocellular carcinoma.Lipid Synthesis Is a Metabolic Liability of Non-Small Cell Lung Cancer.Understanding the Intersections between Metabolism and Cancer Biology.Reenergizing T cell anti-tumor immunity by harnessing immunometabolic checkpoints and machineries.Metabolic rewiring in mutant Kras lung cancer.Exploring cancer metabolism using stable isotope-resolved metabolomics (SIRM).Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials.Use of confocal laser endomicroscopy with a fluorescently labeled fatty acid to diagnose colorectal neoplasms.A Predictive Model for Selective Targeting of the Warburg Effect through GAPDH Inhibition with a Natural Product.AMPK: guardian of metabolism and mitochondrial homeostasis.Reverse engineering the cancer metabolic network using flux analysis to understand drivers of human disease.Oncogene-Driven Metabolic Alterations in Cancer.Targeting Metabolism for Cancer Therapy.Lipid Metabolism and Lipid Droplets in Pancreatic Cancer and Stellate Cells.Early Inhibition of Fatty Acid Synthesis Reduces Generation of Memory Precursor Effector T Cells in Chronic Infection.Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence.Targeting de novo lipogenesis as a novel approach in anti-cancer therapy.Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy.AMPK Re-Activation Suppresses Hepatic Steatosis but its Downregulation Does Not Promote Fatty Liver Development.Acetyl-CoA carboxylase 1 regulates endothelial cell migration by shifting the phospholipid composition.The carnitine system and cancer metabolic plasticity.Recent advances in cancer metabolism: a technological perspective.The mitochondrial citrate carrier, SLC25A1, drives stemness and therapy resistance in non-small cell lung cancer.Glycycoumarin Sensitizes Liver Cancer Cells to ABT-737 by Targeting De Novo Lipogenesis and TOPK-Survivin Axis.p53 and metabolism: from mechanism to therapeutics.Differential Reliance on Lipid Metabolism as a Salvage Pathway Underlies Functional Differences of T Cell Subsets in Poor Nutrient Environments.Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism.Lipid metabolism and carcinogenesis, cancer development.Bone Marrow Adipocyte: An Intimate Partner With Tumor Cells in Bone Metastasis.The contributions of cancer cell metabolism to metastasisIdentification of ceRNA network based on a RNA-seq shows prognostic lncRNA biomarkers in human lung adenocarcinomaPterostilbene inhibits nutrient metabolism and induces apoptosis through AMPK activation in multiple myeloma cellsThe role of YAP/TAZ activity in cancer metabolic reprogramming
P2860
Q30252965-3792275A-C888-4178-802E-4551511BBB14Q33842260-30BD03F8-588F-4BF9-BF19-1FFE6A809A52Q36247876-EA6910C8-9BBF-4894-918E-098FDCF0110DQ36323141-C64291D4-AD36-462D-B36C-7AC22997D3B6Q38733774-2A4AF3BC-D658-4333-8C4C-00C4B1B34FBBQ38764024-A6531A7E-D0F2-477C-BDF1-A320E293A923Q38984784-5F5BDA0D-B15E-4AB3-A6C9-3741C80D4D63Q39001915-DCF1F84B-AB11-4687-A1CF-81E72F716720Q39071340-5603FF37-296C-4733-82DC-51FFE0201567Q39130440-79855BFE-0FC6-4B86-934D-CA511126859BQ39273837-8BE681A2-2E12-423B-BD3C-35B8BB60F565Q39343660-F58CDE80-55EA-493C-864F-E7685104CE91Q39358317-2BF42C59-169B-4B3F-A231-BEC358831DC9Q41339882-B2302411-9587-4F6A-93FB-FA1633F0E883Q41708873-7B418655-3850-4AC1-97A3-6AC2A02A3D0DQ45945650-AF28AC12-8C36-48CD-8A3D-CE54BDCF2E40Q45982416-6FFB1111-BE8F-4B16-ACDF-EF971ED8F72AQ46614710-1A046D59-D5AC-4882-ADE7-6CA5B4F628B1Q47159555-BB45A86A-6B29-49F6-B725-5CAD4A846CC4Q47646742-16E0CAC0-0520-4A30-AC4A-63225F0E8D3BQ47754576-69A1519F-2978-4389-BF8A-E4905111820DQ48019153-93596999-8462-4E39-8F90-0AE4FAE850E0Q48543236-F7B5A0D4-EEDC-4BE8-B22C-07D566F024D7Q48608544-06D7528D-56A0-4D51-AC7F-7E56AD97CA77Q49923401-9CB0F140-35D5-428B-BC03-C99EAA52D86EQ49990861-3C49C1A2-8B85-4DEC-B5F7-38CB436476AAQ50058773-641E0732-C752-4285-AEF8-037B28FDDF08Q51769132-579F9927-1616-426B-8B6C-C9E9FE6B3156Q52587329-CFDDC4C8-AEFF-413F-B64F-15B9525606DEQ52590861-7585DA7E-6669-4708-8F8E-383D08830329Q53701820-51C8961E-30EF-4CBC-B8FA-1BECBBA6A6AFQ55002919-12E06980-844A-4F0C-AE77-AADBBC8E0038Q55255737-DBF54BFB-FB99-4F48-93CD-CA074F117069Q55401962-30A2E050-A1CC-4029-9B1D-EB1F421F5744Q55405747-387C6F06-D856-49C1-85B7-2DB0359EE445Q55655406-A43FE6E4-9E5D-4253-B652-7BE6D7421A6DQ57188839-83D17AB7-B7C5-4530-985F-76CC9DC64BFCQ57788791-DB3F413B-B644-4DAC-AF7A-DFDC74C1ED7DQ58762272-43FC69CD-1A46-44D7-A2EF-BE67D2487758Q58768991-7BFE37FC-1F76-4BC0-A33D-88DC37E648FE
P2860
Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 September 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Inhibition of acetyl-CoA carbo ...... cancer in preclinical models.
@en
Inhibition of acetyl-CoA carbo ...... cancer in preclinical models.
@nl
type
label
Inhibition of acetyl-CoA carbo ...... cancer in preclinical models.
@en
Inhibition of acetyl-CoA carbo ...... cancer in preclinical models.
@nl
prefLabel
Inhibition of acetyl-CoA carbo ...... cancer in preclinical models.
@en
Inhibition of acetyl-CoA carbo ...... cancer in preclinical models.
@nl
P2093
P2860
P356
P1433
P1476
Inhibition of acetyl-CoA carbo ...... cancer in preclinical models.
@en
P2093
Alan Saghatelian
Amanda Hutchins
Christian M Metallo
Geraldine Harriman
H James Harwood
Jeanine L Van Nostrand
Jeremy Greenwood
Laurie Gerken
Lillian J Eichner
Lilliana Vera
P2860
P2888
P304
P356
10.1038/NM.4181
P407
P577
2016-09-19T00:00:00Z